Company CVAbout Gujarat Themis Biosyn Ltd 
Gujarat Themis Biosyn Ltd
Small Cap
Pharmaceuticals & Drugs
Promoted by Kantilal Shah, Gujarat Themis Biosyn Limited was incorporated in 1981 as a joint sector company with Gujarat Industrial Investment Corporation Ltd (GIIC) and Chemosyn (P) Ltd. The Company commenced production in August 1985. It was subsequently taken over in June 1991 by Yuhan Group, South Korea and Pharmaceutical Business Group (India) Ltd. (PBG); a unique consortium of five competing drug companies - Themis Medicare Ltd., Kopran Ltd., Anant & Co., Cadila Health Care Ltd.
Company Coordinates
Company Details
69/C GIDC Industrial Estate, Valsad Dist VAPI Gujarat : 396195
Registrar Details
Link Intime India Pvt Ltd, C-13 Pannalal Silk Compound, L B S Marg, Bhandup , Mumbai
Capital StructureCapital Structure
Present Equity Capital
INR 10.90 Cr
Number of Shares
10.9 Cr
Face Value
INR 1.0
Date
Number
of Shares(Cr)
of Shares(Cr)
Equity
Capital (Rs Cr)
Capital (Rs Cr)
Shares Added
Face Value (Rs)
Reason
09-Aug-2024
10.9
10.90
36321755
1
Bonus Issue
10-Oct-2023
7.26
7.26
58114808
1
Stock Split
07-Jun-2012
1.16
5.80
0
5
Capital Reduction
07-Jun-2012
1.45
7.26
2928702
5
Conversion of Loans
07-Jun-2012
1.16
5.80
0
5
Capital Reduction
07-Jun-2012
1.45
7.26
2928702
5
Conversion of Loans
ShareholdingShareholding Snapshot
Shareholding Compare (%holding)
Majority shareholders
Promoters
Pledged Promoter Holdings
3.3023
Mutual Funds
Held by 5 Schemes (1.16%)
FIIs
Held by 8 FIIs (1.47%)
Promoter with highest holding
Pharmaceutical Business Group [india] Ltd (47.02%)
Highest Public shareholder
Quant Mutual Fund - Quant Manufacturing Fund (1.15%)
Individual Investors Holdings
19.75%
Board of Directors
Management
Designation
Remuneration
Dinesh S Patel
Chairman & Non Executive Dir.
0
Sachin D Patel
Non Executive Director
0
VIJAY GOPI KISHAN AGARWAL
Independent Non Exe. Director
3.45 lacs
Kirandeep Madan
Independent Non Exe. Director
2.5 lacs
Vikram D Sanghvi
Independent Non Exe. Director
3.45 lacs
Siddharth Y Kusumgar
Independent Non Exe. Director
2.8 lacs
Raw MaterialsRaw Materials Dashboard
Raw Materials
Amount(Rs Cr)
% of RM Cost
No Data Available for Raw Material Segmentation
No Data Available
Finished Goods Finished Goods Dashboard
Finished Goods
Amount(Rs Cr)
% of Sales Turnover
Conversion/Job Work Charges Received
39.83
97.02%
Lova Boronate
1.08
2.62%
Scrap
0.15
0.36%
Conversion/Job Work Charges Received
Conversion/Job Work Charges Received
Lova Boronate
Lova Boronate
Scrap
Scrap
Stock DNARevenue and Profits:
Net Sales:
40 Cr
(Quarterly Results - Dec 2024)
Net Profit:
13 Cr
Pharmaceuticals & Drugs
INR 2,910 Cr (Small Cap)
51.00
33
0.07%
-0.03
23.57%
12.04
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
